Boston Scientific Corporation $BSX Stock Position Reduced by Brasada Capital Management LP

Key Points

• Brasada Capital Management LP has reduced its stake in Boston Scientific by 5.7%, selling 5,412 shares, which now make up 1.7% of its investment portfolio.
• Boston Scientific's recent earnings report indicated a 22.8% year-over-year revenue increase and an EPS of $0.75, surpassing analysts’ expectations.
• Several analysts have upgraded Boston Scientific's stock rating, with an average target price of $117.50, suggesting a positive outlook for the company's performance.

Brasada Capital Management LP cut its holdings in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 5.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 89,865 shares of the medical equipment provider's stock after selling 5,412 shares during the quarter. Boston Scientific comprises approximately 1.7% of Brasada Capital Management LP's portfolio, making the stock its 18th biggest holding. Brasada Capital Management LP's holdings in Boston Scientific were worth $9,066,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in BSX. Brighton Jones LLC increased its stake in Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock worth $2,445,000 after acquiring an additional 226 shares during the last quarter. Bank Pictet & Cie Europe AG increased its stake in Boston Scientific by 40.8% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock worth $6,529,000 after acquiring an additional 21,173 shares during the last quarter. Highview Capital Management LLC DE increased its stake in Boston Scientific by 6.2% during the fourth quarter. Highview Capital Management LLC DE now owns 24,507 shares of the medical equipment provider's stock worth $2,189,000 after acquiring an additional 1,439 shares during the last quarter. Rehmann Capital Advisory Group increased its stake in Boston Scientific by 6.9% during the fourth quarter. Rehmann Capital Advisory Group now owns 5,245 shares of the medical equipment provider's stock worth $468,000 after acquiring an additional 339 shares during the last quarter. Finally, Freestone Grove Partners LP acquired a new stake in Boston Scientific during the fourth quarter worth about $26,702,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Stock Up 0.3%

BSX traded up $0.38 on Thursday, reaching $107.91. The company's stock had a trading volume of 3,255,126 shares, compared to its average volume of 7,459,749. The stock has a market cap of $159.89 billion, a price-to-earnings ratio of 64.27, a price-to-earnings-growth ratio of 2.54 and a beta of 0.65. Boston Scientific Corporation has a 1 year low of $80.50 and a 1 year high of $108.94. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The business's 50 day moving average is $104.71 and its 200 day moving average is $102.18.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. The firm had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.Boston Scientific's revenue for the quarter was up 22.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Yoshiaki Fujimori sold 2,901 shares of the stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total value of $310,377.99. Following the completion of the transaction, the director owned 2,081 shares of the company's stock, valued at approximately $222,646.19. This represents a 58.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $5,231,500.00. Following the completion of the transaction, the executive vice president directly owned 178,342 shares of the company's stock, valued at $18,659,923.46. This represents a 21.90% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 174,214 shares of company stock worth $18,397,457. Company insiders own 0.50% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have commented on BSX. Jefferies Financial Group restated a "hold" rating on shares of Boston Scientific in a research note on Monday, July 21st. Oppenheimer increased their target price on Boston Scientific from $110.00 to $118.00 and gave the company a "market perform" rating in a research note on Thursday, July 24th. Leerink Partners assumed coverage on Boston Scientific in a research note on Monday, June 16th. They issued an "outperform" rating and a $118.00 target price for the company. Citigroup reiterated a "buy" rating and issued a $125.00 target price (up previously from $119.00) on shares of Boston Scientific in a research note on Thursday, May 22nd. Finally, Robert W. Baird increased their target price on Boston Scientific from $117.00 to $123.00 and gave the company an "outperform" rating in a research note on Thursday, July 24th. Three research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $117.50.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.